Zum Hauptinhalt springen

Epoxy resin composition, curing agent, and curing accelerator

Kaneko, Masami ; Ono, Kazuo ; et al.
2014
Online Patent

Titel:
Epoxy resin composition, curing agent, and curing accelerator
Autor/in / Beteiligte Person: Kaneko, Masami ; Ono, Kazuo ; Amanokura, Natsuki ; Kamegaya, Naoyuki
Link:
Veröffentlichung: 2014
Medientyp: Patent
Sonstiges:
  • Nachgewiesen in: USPTO Patent Grants
  • Sprachen: English
  • Patent Number: 8,623,942
  • Publication Date: January 07, 2014
  • Appl. No: 13/138568
  • Application Filed: March 09, 2010
  • Assignees: Nippon Soda Co., Ltd. (Tokyo, JP)
  • Claim: 1. A liquid curable epoxy resin composition containing the following component (A) and component (B): (A) an epoxy resin; and (B) a clathrate containing (b1) a pyridine derivative represented by formula (I): [chemical expression included] wherein R represents a hydroxy group, a nitro group, an alkyl group, an alkoxy group, an amino group, a sulfo group, an acetamide group, a hydrazine group, or a carboxyl group, and n represents an integer of 1 to 5; and when there are a plurality of R, R may be the same or different, and (b2) at least one selected from the group consisting of 1,8-diazabicyclo[5.4.0]undecene-7 and an imidazole compound represented by formula (II): [chemical expression included] wherein R 1 represents a hydrogen atom, a C1-C10 alkyl group, an aryl group, an arylalkyl group, or a cyanoethyl group, and R 2 to R 4 each represent a hydrogen atom, a nitro group, a halogen atom, a C1-C20 alkyl group, a C1-C20 alkyl group substituted by a hydroxy group, an aryl group, an arylalkyl group, or a C1-C20 acyl group.
  • Claim: 2. The curable epoxy resin composition according to claim 1 , further containing an organic solvent.
  • Claim: 3. The curable epoxy resin composition according to claim 2 , wherein the organic solvent is a polar solvent.
  • Claim: 4. The curable epoxy resin composition according to claim 2 , wherein when methyl ethyl ketone is saturated with the clathrate of the component (B) at 25° C., a concentration of the component (b2) liberated in the methyl ethyl ketone is 5000 ppm or less.
  • Claim: 5. The curable epoxy resin composition according to claim 4 , wherein the organic solvent is a polar solvent.
  • Claim: 6. The curable epoxy resin composition according to claim 1 , wherein the epoxy resin is a liquid epoxy resin.
  • Claim: 7. A curing agent or a curing accelerator for a liquid curable resin composition, containing the following clathrate (B): (B) a clathrate containing (b1) a pyridine derivative represented by formula (I): [chemical expression included] wherein R represents a hydroxy group, a nitro group, an alkyl group, an alkoxy group, an amino group, a sulfo group, an acetamide group, a hydrazine group, or a carboxyl group, and n represents an integer of 1 to 5; and when there are a plurality of R, R may be the same or different, and (b2) at least ne selected from the group consisting of 1,8-diazabicyclo[5.4.0]undecene-7 and an imidazole compound represented by formula (II): [chemical expression included] wherein R 1 represents a hydrogen atom, a C1-C10 alkyl group, an aryl group, an arylalkyl group, or a cyanoethyl group, and R 2 to R 4 each represent a hydrogen atom, a nitro group, a halogen atom, a C1-C20 alkyl group, a C1-C20 alkyl group substituted by a hydroxy group, an aryl group, an arylalkyl group, or a C1-C20 acyl group.
  • Claim: 8. The curing agent or the curing accelerator according to claim 7 , wherein the liquid curable resin composition comprises an organic solvent.
  • Claim: 9. The curing agent or the curing accelerator according to claim 7 , wherein the liquid curable resin composition comprises a liquid epoxy resin.
  • Claim: 10. A clathrate containing: (b1) a pyridine derivative represented by formula (I): [chemical expression included] wherein R represents a hydroxy group, a nitro group, an alkyl group, an alkoxy group, an amino group, a sulfo group, an acetamide group, a hydrazine group, or a carboxyl group, and n represents an integer of 1 to 5; and when there are a plurality of R, R may be the same or different, and (b2) at least one selected from the group consisting of 1,8-diazabicyclo[5.4.0]undecene-7 and an imidazole compound represented by formula (II): [chemical expression included] wherein R 1 represents a hydrogen atom, a C1-C10 alkyl group, an aryl group, an arylalkyl group, or a cyanoethyl group, and R 2 to R 4 each represent a hydrogen atom, a nitro group, a halogen atom, a C1-C20 alkyl group, a C1-C20 alkyl group substituted by a hydroxy group, an aryl group, an arylalkyl group, or a C1-C20 acyl group.
  • Current U.S. Class: 523/461
  • Patent References Cited: 3746686 July 1973 Marshall et al. ; 3847612 November 1974 Winslow ; 4244989 January 1981 Noomen ; 4420605 December 1983 Kaufman ; 5153239 October 1992 Kitagawa et al. ; 6727325 April 2004 Suzuki et al. ; 2003/0008991 January 2003 Holmes et al. ; 2003/0054146 March 2003 Kim et al. ; 2010/0016475 January 2010 Doering et al. ; 2010/0022744 January 2010 Kaneko et al. ; 2010/0179250 July 2010 Ono et al. ; 2012/0004349 January 2012 Kaneko et al. ; 2012/0196991 August 2012 Ono et al. ; 2013/0059942 March 2013 Ono et al. ; 2013/0158231 June 2013 Kamegaya et al. ; 0 057 325 August 1982 ; 0 621 256 October 1994 ; 0 949 286 October 1999 ; 49-032999 March 1974 ; 56-100748 August 1981 ; 57-135870 August 1982 ; 58-076420 May 1983 ; 60-252620 December 1985 ; 01-096278 April 1989 ; 4-2638 January 1992 ; 04-266922 September 1992 ; 05-194711 August 1993 ; 06-100662 April 1994 ; 08-151372 June 1996 ; 09-143250 June 1997 ; 10-511718 November 1998 ; 10-316639 December 1998 ; 10-324826 December 1998 ; 11-071449 March 1999 ; 11-158253 June 1999 ; 2000-248053 September 2000 ; 2001-172225 June 2001 ; 2002-020714 January 2002 ; 2002-047337 February 2002 ; 2004-503632 February 2004 ; 2004-210677 July 2004 ; 2004-300041 October 2004 ; 2004-300256 October 2004 ; 2004-307545 November 2004 ; 2006-016542 January 2006 ; 2006-206731 August 2006 ; 2007-039449 February 2007 ; 200909467 March 2009 ; WO 96/20253 July 1996 ; WO 2006/128542 December 2006 ; WO 2008/075427 June 2008 ; WO 2008/143314 November 2008 ; WO 2009037862 March 2009
  • Other References: Final Office Action dated Jun. 14, 2013 in copending U.S. Appl. No. 12/733,462. cited by applicant ; International Search Report dated Jun. 15, 2010, in PCT/JP2010/001663, 2 pages. cited by applicant ; Chen et al., “Synthesis, structures of cobalt/copper complexes and magnetic property of copper complex with the mixed ligands 5-nitro-1,3-benzenedicarbmlic acid and imidazole,” Inorganic Chemistry Communications, 2006, 9:300-303. cited by applicant ; Lin et al., “Aromatic Polyoxyalkylene Amidoamines as Curatives for Epoxy Resins—Derivatives from t-Butyl Isophthalic Acid,” Journal of Polymer Research, Apr. 1996, 3(2):97-104. cited by applicant ; Luo et al., “A Novel Bilayer Cobalt(II)—Organic Framework with Nanoscale Channels Accommodating Large Organic Molecules,” Inorganic Chemistry, 2003, 42:4486-4488. cited by applicant ; Office Action dated Feb. 1, 2013 in copending U.S. Appl. No. 12/733,462. cited by applicant ; It Final Office Action dated Sep. 7, 2012 in copending U.S. Appl. No. 12/733,462. cited by applicant ; Office Action dated Sep. 24, 2013, in copending U.S. Appl. No. 13/331,772. cited by applicant
  • Primary Examiner: Feely, Michael J
  • Attorney, Agent or Firm: Foley & Lardner LLP

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -